- RYAH has released April 2021 Patients Patterns in New York Report to bring invaluable data-driven insights within the plant-based health industry amid recent recreational cannabis legislation change in this state.
- The company leveraged data from 4,387 New York patients within the RYAH Data ecosystem to discover New York-based patients’ profiles, including their preferences and medical reasons for use.
- As an authority in dose-control technology for plant-based medicine, RYAH appears well placed to capitalize on growing market opportunities.
RYAH Group (CSE: RYAH) (formerly known as Prime Blockchain Inc.) has announced the release of its “April 2021 Patients Patterns in New York Report,” covering data generated by 4,387 patients from New York who logged their sessions within the RYAH Data ecosystem between January 1, 2018, and April 15, 2021 (https://ibn.fm/ScF8T). As an authority within the dose-control technology for plant-based medicine, RYAH leverages access to a wealth of data helping open up new knowledge-enabled possibilities within the health industry. The newly published report is the latest such initiative — especially invaluable since the recent legislative approval of recreational cannabis in March 2021.
Home to one of the wealthiest cities in the world, New York state accounts for 8% of US GDP. It is expected to become one of the largest US plant markets, with recreational cannabis sales potentially reaching $1.2 billion by 2023 and up to $4.2 billion by 2027. With these market expectations, it is of critical importance to understand who a New York-based patient is, what their preferences are, and what medical conditions they use cannabis for.
As a data analytics health care company collecting anonymized data generated by patients, RYAH is ideally placed to answer these questions. The Company is committed to developing cutting-edge technology to generate powerful analytics by combining dosing data with lab test information and patient feedback to create a personalized self-optimizing experience.
The report gives invaluable insights into the New York medical cannabis space, comparing it to the national average. It reveals that these patients are more likely to be male (65.5%) than patients at the national level (54.8%) while they have slightly less experience with the plant and use it less frequently. For example, 7% of patients from New York use it daily, compared to the national average of 8.4%. On the other hand, and in line with national averages, New York patients prefer cultivars with higher THC content or a CBD-rich profile. More sessions from New York-based patients were logged on the RYAH platform for anxiety, social anxiety disorder, and ADHD than patients from other parts of the country. RYAH Data ecosystem also reveals that conditions such as stress and depression are more prevalent in New York patients.
After launching in a limited capacity in 2016, New York State’s medical cannabis program served more than 143,000 patients. In March 2021, the state approved the legislation covering recreational cannabis, becoming the 15th state to legalize recreational use (https://ibn.fm/rFWL5). Several amendments are introduced to improve access to medical cannabis, covering a wide range of qualifying conditions, including cancer, HIV, Parkinson’s disease, multiple sclerosis, spinal cord injury, epilepsy, inflammatory bowel disease, neuropathy, Huntington’s disease, PSTD and chronic pain. As a go-to provider of data analytics expertise for the plant-based medical industry, RYAH appears ideally placed to capitalize on the growing market opportunity as New York positions itself to become one of the nation’s largest markets of legal cannabis and the plant-based legislation continues to evolve nationwide.
For more information, visit the company’s website at www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the Company’s newsroom at https://ibn.fm/RYAH
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.